Praxis Precision Medicines Inc

PRAX has broken multi-week support around $335 (Support Failure) and is trading below its 9/20 EMAs and the 50-day SMA, confirming bearish momentum. The primary Support Failure pattern signals sellers overwhelming buyers, with further downside likely toward the rising 200-day SMA near $311. Short-term momentum is negative, as price rejects resistance at declining EMAs. Medium-term bias remains bearish in Stage 3 distribution. While RSI is oversold, the structural context favors selling now into any rally under EMA resistance. The long-term uptrend above the 200-day SMA remains intact but is currently overshadowed by distribution dynamics.

• ↑$1.4B in cash and equivalents at Q1 2026 funds R&D and launch through 2028
• ↑NDA for ulexacultamide and relutrigine accepted; combined peak sales >$10B
• ↓Q1 2026 operating expenses surged 100% YoY to $106M, straining cash burn